Evidence map›Paper›PMID 35358723›Full record

ArticleInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2022

Serological surveillance of healthcare workers to evaluate natural infection- and vaccine-derived immunity to SARS-CoV-2 during an outbreak in Dili, Timor-Leste.

Paul Arkell, Celia Gusmao, Sarah L Sheridan, Maria Y Tanesi, Nelia Gomes, Tessa Oakley, Johanna Wapling, Lucsendar Alves, Stacey Kopf, Nevio Sarmento and 12 more

Open access · goldAbstract read
In one paragraph

Article in International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. The COVID-19 laboratory response in Timor-Leste; a story of collaboration.The Lancet regional health. Southeast Asia · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 4 institutions in 4 countries.

Paul ArkellGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia; Imperial College, London, UK. Electronic address: paularkell@doctors.org.uk.
Celia GusmaoHospital Nacional Guido Valadares, Dili, Timor-Leste.
Sarah L SheridanNational Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia.
Maria Y TanesiGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
Nelia GomesGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
Tessa OakleyGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
Johanna WaplingGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
Lucsendar AlvesGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
Stacey KopfGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
Nevio SarmentoGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
Ismael Da Costa BarretoWorld Health Organisation, Dili, Timor-Leste.
Salvador AmaralGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
Anthony Dk DraperGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
Danina CoelhoMinistry of Health, Dili, Timor-Leste.
Helio GuterresHospital Nacional Guido Valadares, Dili, Timor-Leste.
Antonio SallesLaboratório Nacional de Saúde, Dili, Timor-Leste.
Filipe MachadoMinistry of Health, Dili, Timor-Leste.
Nicholas Ss FancourtGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
Jennifer YanGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
Ian MarrGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
Kristine MacartneyNational Centre for Immunisation Research and Surveillance, Westmead, NSW, Australia.
Joshua R FrancisGlobal and Tropical Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia. Electronic address: josh.francis@menzies.edu.au.
Charles Darwin University · AUUniversidade da Paz · TLNational Centre for Immunisation Research & Surveillance · AUWorld Health Organization - Pakistan · PK

Funding

World Health Organization 001
6 · The paper itself

Abstract

Background Serosurveillance can be used to investigate the extent and distribution of immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) within a population. Characterisation of humoral immune responses gives insight into whether immunity is infection- or vaccine-derived. Methods A longitudinal study of health care workers (HCWs) in Dili, Timor-Leste, was conducted during vaccine rollout (ChAdOx1) and a concurrent SARS-CoV-2 outbreak. Results A total of 324 HCWs were included at baseline (April-May 2021). Out of those, 32 (9.9%) were seropositive for anti-nucleocapsid protein (anti-N) IgG antibodies, indicating a significant sub-clinical infection among HCWs early in the local outbreak. Follow-up was conducted in 157 (48.5%) participants (July-September 2021), by which time there had been high uptake of vaccination (91.7%), and 86.0% were seropositive for anti-spike protein antibodies. Acquisition of anti-N antibodies was observed in partially vaccinated HCWs (30/76, 39.5%), indicating some post-dose-1 infections. Discussion Serosurveillance of HCWs may provide early warning of SARS-CoV-2 outbreaks and should be considered in non-endemic settings, particularly where there is limited availability/uptake of testing for acute infection. Characterisation of humoral immune responses may be used to assess vaccine impact and coverage. Such studies should be considered in national and international efforts to investigate and mitigate against future emerging pathogens.

Indexed as

COVID-19VaccinesAntibodies, ViralCOVID-19 VaccinesDisease OutbreaksHealth PersonnelHumansLongitudinal StudiesSARS-CoV-2Timor-LesteVaccinationAntibodies, ViralCOVID-19 VaccinesVaccinesChAdOx1COVID-19healthcare workerSARS-CoV-2serological surveillancevaccination

Identifiers

PMID35358723
PMCPMC8958849
OpenAlexW4221122330

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.